(Q35549732)

8 August 2017

1 reference

title

Update on the National Cholesterol Education Program Adult Treatment Panel III guidelines: getting to goal (English)

1 reference

8 August 2017

Update on the National Cholesterol Education Program Adult Treatment Panel III Guidelines: Getting to Goal (English)

1 reference

https://api.crossref.org/works/10.1592/PHCO.23.11.26S.32710

17 March 2024

author name string

James M. McKenney

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14524636

17 March 2024

language of work or name

English

0 references

publication date

1 September 2003

1 reference

full work available at URL

8 August 2017

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1592%2Fphco.23.11.26S.32710

1 reference

https://api.crossref.org/works/10.1592/PHCO.23.11.26S.32710

https://onlinelibrary.wiley.com/doi/full/10.1592/phco.23.11.26S.32710

17 March 2024

1 reference

https://api.crossref.org/works/10.1592/PHCO.23.11.26S.32710

17 March 2024

1 reference

8 August 2017

volume

23

1 reference

8 August 2017

issue

9 Pt 2

1 reference

8 August 2017

page(s)

26S-33S

1 reference

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

8 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.11.26S.32710

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.11.26S.32710

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.11.26S.32710

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.11.26S.32710

Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.11.26S.32710

Current, new and future treatments in dyslipidaemia and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.11.26S.32710

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.11.26S.32710

Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.11.26S.32710

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.11.26S.32710

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.11.26S.32710

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.11.26S.32710

Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.11.26S.32710

Evaluating novel cardiovascular risk factors: can we better predict heart attacks?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.11.26S.32710

Management of hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.11.26S.32710

Hypertriglyceridemia as a cardiovascular risk factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.11.26S.32710

High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High--Density Lipoprotein Intervention Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.11.26S.32710

New National Cholesterol Education Program III guidelines for primary prevention lipid-lowering drug therapy: projected impact on the size, sex, and age distribution of the treatment-eligible population

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.23.11.26S.32710

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

21 January 2018

4

1 reference

https://api.crossref.org/works/10.1592/PHCO.23.11.26S.32710

Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials

17 March 2024

7

1 reference

https://api.crossref.org/works/10.1592/PHCO.23.11.26S.32710

Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the post coronary artery bypass graft trial. Post CABG Investigators

17 March 2024

11

1 reference

https://api.crossref.org/works/10.1592/PHCO.23.11.26S.32710

Prediction of Coronary Heart Disease Using Risk Factor Categories

17 March 2024

17

1 reference

https://api.crossref.org/works/10.1592/PHCO.23.11.26S.32710

AHA Dietary Guidelines: revision 2000: A statement for healthcare professionals from the Nutrition Committee of the American Heart Association

17 March 2024

19

1 reference

https://api.crossref.org/works/10.1592/PHCO.23.11.26S.32710

Cholesterol reduction yields clinical benefit: impact of statin trials

17 March 2024

21

1 reference

https://api.crossref.org/works/10.1592/PHCO.23.11.26S.32710

17 March 2024

Identifiers

1 reference

8 August 2017

1 reference